European Sterile Fill-Finish CDMO 2026: Aseptic Injectables, Vaccines, Biologics, and ATMP Sterile Capacity

Germany concentrates the directory-surfaced large-cap aseptic fill-finish capacity. Vetter Pharma (Ravensburg) is the directory’s anchor aseptic injectable fill-finish operator, providing prefilled syringe, cartridge, and vial sterile fill-finish at commercial scale for biologics + small-molecule injectables. Vetter operates clinical and commercial manufacturing sites across Ravensburg (Schützenstraße HQ + Ravensburg South) and Langenargen alongside US sites — the directory entry covers the German anchor. IDT Biologika (Dessau-Roßlau) provides viral vaccine + cell and gene therapy + fill-finish CDMO services with experience across COVID-19 vaccine fill-finish + adjuvanted vaccines + viral-vector therapeutics. Boehringer Ingelheim (Ingelheim am Rhein) runs biopharmaceutical production + therapeutic manufacturing including in-house and contract biologics fill-finish at scale.

Denmark hosts two directory operators in biologics + vaccine fill-finish. FUJIFILM Diosynth Biotechnologies Hillerød is the directory-surfaced large-scale biologics CDMO providing process development + commercial biopharmaceutical manufacturing + fill-finish, originally a Biogen biopharmaceutical site, acquired by FUJIFILM in August 2019 and now part of the FUJIFILM Diosynth global network with major capacity expansions announced 2021–2024. Bavarian Nordic (Kvistgård) develops and manufactures vaccines including the MVA-BN platform (Jynneos / Imvanex / Imvamune for smallpox + mpox, FDA + EMA approved) plus biodefense vaccines + chikungunya vaccine Vimkunya (FDA approved February 2025) — including in-house fill-finish operations.

Finland and the Baltics add ATMP and biopharm fill-finish capacity. 3P Biovian (Turku, Finland) is the merged Spanish + Finnish CDMO providing biologics + viral vectors + plasmid DNA + aseptic fill-finish using mammalian and microbial platforms — the Turku site provides aseptic fill-finish for biologics + viral-vector ATMP. Kuopio Center for Gene and Cell Therapy (Kuopio, Finland) provides GMP viral-vector manufacturing + AAV + adenovirus + lentivirus + ATMP CDMO services including ATMP fill-finish for cell + gene therapy programmes — the directory-surfaced Finnish ATMP CDMO. Northway Biotech (Vilnius, Lithuania) provides biopharm CDMO + cell line development + biologics manufacturing including aseptic fill-finish for regional supply. The Cell & Gene Therapy Europe 2026 brief covers the wider ATMP CDMO layer including Antion Biosciences and Fuse Vectors.

The Baltic + Polish sterile dosage + hospital-medicines layer concentrates at four directory operators. Pharmidea (Olaine, Latvia) develops and manufactures sterile pharmaceutical products including injectable + ophthalmic + hospital medicines. Kalceks (Riga, Latvia) is the directory-surfaced Latvian sterile dosage forms + hospital medicines + finished dosage manufacturer. Polpharma Starogard Gdański (Poland) is the largest Polish pharmaceutical manufacturer providing sterile production + generics + APIs + drug development at integrated scale. Lotos Pharma (Mārupe, Latvia) provides pharmaceutical manufacturing + consumer health adjacent to the sterile dosage layer. The Polish Biotech Landscape 2026 brief covers Polpharma + Polpharma Biologics in wider context.

Sweden and Finland add Nordic sterile manufacturing + vaccine fill-finish. Recipharm (Stockholm) provides CDMO operations + sterile manufacturing + pharmaceutical supply across multiple modalities for global sponsors. Valneva (Solna manufacturing site, Sweden; HQ Saint-Herblain, France) develops and manufactures vaccines including IXIARO (Japanese encephalitis), DUKORAL (cholera), and IXCHIQ (chikungunya, FDA + EMA approved 2023–2024) with vaccine fill-finish capacity at its Solna + European sites. The European Vaccines Landscape 2026 brief covers Valneva and Bavarian Nordic in wider vaccine context.

European sterile fill-finish connects to a primary-packaging + drug-delivery device + cold-chain ecosystem covered in adjacent briefs. Gerresheimer (Düsseldorf, Germany) provides primary packaging + drug delivery systems including vials, syringes, and cartridges for sterile manufacturing — covered in the European Cardiometabolic Therapeutics 2026 brief. Ypsomed (Burgdorf, Switzerland) provides autoinjector + pen + pump device platforms — covered in cardiometabolic context. The European Pharma Cold Chain Logistics 2026 brief covers GDP-aligned distribution of fill-finished sterile products. The European CDMO Capacity 2026 brief covers the wider European CDMO layer including Lonza Visp, Wacker Biotech, AGC Biologics, and integrated biologics CDMO.

Match the decision to the modality + scale. Large-cap aseptic injectable fill-finish (prefilled syringes, cartridges, vials, biologics + small molecule): Vetter Pharma (Ravensburg). Viral vaccine + CGT + adjuvanted vaccine fill-finish: IDT Biologika (Dessau-Roßlau). Large-scale biologics CDMO + commercial biopharma + fill-finish: FUJIFILM Diosynth Biotechnologies (Hillerød). Vaccine + biodefense fill-finish (MVA-BN, chikungunya): Bavarian Nordic (Kvistgård). In-house biopharmaceutical production + therapeutic manufacturing: Boehringer Ingelheim (Ingelheim am Rhein). Sterile CDMO + cross-modality supply: Recipharm (Stockholm). Aseptic fill-finish + viral-vector + plasmid DNA CDMO: 3P Biovian (Turku). ATMP cell + gene therapy fill-finish: Kuopio Center for Gene and Cell Therapy (Kuopio). Biopharm CDMO + biologics fill-finish for Baltic regional supply: Northway Biotech (Vilnius). Sterile pharmaceutical products + injectable + ophthalmic: Pharmidea (Olaine). Sterile dosage forms + hospital medicines: Kalceks (Riga). Integrated Polish sterile production + APIs + generics at scale: Polpharma Starogard Gdański. Vaccine commercial fill-finish + Japanese encephalitis + cholera + chikungunya: Valneva (Solna, Sweden manufacturing site). The European CDMO Capacity 2026 brief covers cross-modality CDMO selection.